Literature DB >> 21270408

HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding.

Des C Jones1, Vasilis Kosmoliaptsis, Richard Apps, Nicolas Lapaque, Isobel Smith, Azumi Kono, Chiwen Chang, Louise H Boyle, Craig J Taylor, John Trowsdale, Rachel L Allen.   

Abstract

Leukocyte Ig-like receptors (LILRs) are a family of innate immune receptors predominantly expressed by myeloid cells that can alter the Ag presentation properties of macrophages and dendritic cells. Several LILRs bind HLA class I. Altered LILR recognition due to HLA allelic variation could be a contributing factor in disease. We comprehensively assessed LILR binding to >90 HLA class I alleles. The inhibitory receptors LILRB1 and LILRB2 varied in their level of binding to different HLA alleles, correlating in some cases with specific amino acid motifs. LILRB2 displayed the weakest binding to HLA-B*2705, an allele genetically associated with several autoimmune conditions and delayed progression of HIV infection. We also assessed the effect of HLA class I conformation on LILR binding. LILRB1 exclusively bound folded β(2)-microglobulin-associated class I, whereas LILRB2 bound both folded and free H chain forms. In contrast, the activating receptor LILRA1 and the soluble LILRA3 protein displayed a preference for binding to HLA-C free H chain. To our knowledge, this is the first study to identify the ligand of LILRA3. These findings support the hypothesis that LILR-mediated detection of unfolded versus folded MHC modulates immune responses during infection or inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270408     DOI: 10.4049/jimmunol.1003078

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

Review 1.  The multi-faceted nature of HLA class I dimer molecules.

Authors:  Elaine C Campbell; Antony N Antoniou; Simon J Powis
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

2.  Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Authors:  Hugo G Hilton; Luca Vago; Anastazia M Older Aguilar; Achim K Moesta; Thorsten Graef; Laurent Abi-Rached; Paul J Norman; Lisbeth A Guethlein; Katharina Fleischhauer; Peter Parham
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 3.  LILRB receptor-mediated regulation of myeloid cell maturation and function.

Authors:  William van der Touw; Hui-Ming Chen; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Immunol Immunother       Date:  2017-06-21       Impact factor: 6.968

Review 4.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

5.  Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding.

Authors:  Gol Nam; Yi Shi; Myongchol Ryu; Qihui Wang; Hao Song; Jun Liu; Jinghua Yan; Jianxun Qi; George F Gao
Journal:  Protein Cell       Date:  2013-08-17       Impact factor: 14.870

Review 6.  Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations.

Authors:  Kouyuki Hirayasu; Hisashi Arase
Journal:  J Hum Genet       Date:  2015-06-04       Impact factor: 3.172

7.  Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells.

Authors:  Richard Apps; Zhaojing Meng; Gregory Q Del Prete; Jeffrey D Lifson; Ming Zhou; Mary Carrington
Journal:  J Immunol       Date:  2015-03-09       Impact factor: 5.422

8.  Genome-wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus.

Authors:  Danielle Malheiros; Rodrigo A Panepucci; Ana M Roselino; Amélia G Araújo; Marco A Zago; Maria Luiza Petzl-Erler
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

9.  Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair.

Authors:  Arman A Bashirova; Richard Apps; Nicolas Vince; Yelizaveta Mochalova; Xu G Yu; Mary Carrington
Journal:  Immunogenetics       Date:  2013-10-06       Impact factor: 2.846

10.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.